Last reviewed · How we verify
NCT06225310: KPT-IST-391
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Phase 1 trial testing Selinexor in Multiple Myeloma in Relapse in 30 participants. Currently enrolling.
1 April 2027
Quick facts
| Lead sponsor | Oncotherapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 6 August 2024 |
| Primary completion | 1 April 2027 |
| Estimated completion | 1 May 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Selinexor — full drug profile →
- Ruxolitinib (RUXOLITINIB) — full drug profile →
- Methylprednisolone (methylprednisolone) — full drug profile →
Conditions studied
- Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
- Multiple Myeloma, Refractory — all drugs for Multiple Myeloma, Refractory →
Sponsor
Oncotherapeutics — full company profile →
Who can join
Eligibility, any sex, with Multiple Myeloma in Relapse or Multiple Myeloma, Refractory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.
Aumann WK, Kazi R, Harrington AM, Wechsler DS. · · 2024 · cited 3× · PMID 39161560 · DOI 10.3389/or.2024.1427497 -
Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?
Sokolova V, Gruber R, Pammer LM, Kocher F, et al · · 2024 · cited 1× · PMID 39729162 · DOI 10.1007/s11033-024-10169-5
Verify or expand the search:
- PubMed search for NCT06225310
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Selinexor
Trials testing the same drug.
- NCT07447817 — Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias · Phase 2 · not yet recruiting
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07204041 — Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory · Phase 2 · active not recruiting
- NCT06966154 — A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Se · Phase 1, PHASE2 · recruiting
- NCT06900088 — Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients · Phase 2 · not yet recruiting
Other recruiting trials for Multiple Myeloma in Relapse
Currently open trials in the same condition.
- NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06822972 — HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · Phase 2 · recruiting
- NCT07032129 — Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07248176 — Universal CAR-T Cell Therapy for MM · NA · recruiting
- NCT06846905 — Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. · recruiting
Other Oncotherapeutics trials
Trials by the same sponsor.
- NCT06115135 — A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT04519476 — Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. · Phase 1 · unknown
- NCT03733691 — Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients · Phase 2 · terminated
- NCT03104270 — Combination Study for High Risk Multiple Myeloma Patients · Phase 2 · terminated
- NCT02188368 — Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06225310 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oncotherapeutics
- Last refreshed: 16 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06225310.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing